TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02014558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Participants received 200 mg voriconazole tablets daily every 12 hours starting from day 16 of cycle 1 through day 1 of cycle 2.
Study: NCT01352052

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interdisciplinary rehabilitation
Description: A two-weeks non-residential, group-based, psycho-educative, multi-component treatment course conducted by an interdisciplinary team consisting of a rheumatologist, a nurse, occupational therapists, physical therapists, and a psychologist. The rehabilitation Programme comprises of a combination of lectures and group discussions, as well as instructions during physical exercise and task performance. The main focus is on education and adaptations in everyday life. There is a scheduled Programme for every day, with a daily time schedule between four and six hours. There will be a maximum of eight participants in each group.
Study: NCT02344472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: HER2 targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Chemotherapy
Study: NCT03781544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: A single i.v. infusion of Tramadol (dose: 400mg/100ml) will be administered to the participants (treatment arm).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: A single i.v. infusion of Paracetamol (dose: 1g/100ml) will be administered to the participants (control arm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: A single i.v. infusion of Diclofenac (dose: 75mg/100ml) will be administered to the participants (treatment arm).
Study: NCT03947203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social media
Description: Provided pamphlet and a private Facebook group where informational messages and content relating to oral health will be shared
Study: NCT01595711

Intervention type: DEVICE
Intervention: Pain Monitor
Description: Measurement of cutaneous conductance
Study: NCT02672228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MalariaSense device
Description: All participants enrolled in the study will be assessed for malaria using the intervention device called MalariaSense technology
Study: NCT02414451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Week 1: 40 mg propranolol (1 capsule, nightly) Week 2: 80 mg propranolol (2 40mg capsules, morning \& night) Weeks 3 - 8: 100 mg propranolol (3 capsules, 40 mg/morning, 20mg/afternoon, \& 40mg/night) Week 9: 60 mg propranolol (2 capsules, 40 mg/morning \& 20mg/night) Week 10: 20 mg propranolol (1 capsule, nightly) Week 11: no capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via lactose-filled oral capsule(s) daily for a period of 10 weeks. The schedule of placebo administration will be as follows:~Week 1: 1 capsule, nightly Week 2: 2 capsules, morning \& night Weeks 3 - 8: 3 capsules, morning, afternoon, \& night Week 9: 2 capsules, morning \& night Week 10: 1 capsule, nightly Week 11: no capsules
Study: NCT03180593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 80 mg
Description: Compare office and 24-hour Blood Pressure Control and regression of Left Ventricular Hypertrophy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 80 mg
Description: Compare office and 24-hour Blood Pressure Control and regression of Left Ventricular Hypertrophy
Study: NCT03173027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fangji Huangqi pill or Fangji Huangqi pill placebo
Description: For the treatment group (Fangji Huangqi pill group), patients will administrate Fangji Huangqi pill (4 g) in 200 milliliter hot water as the instruction and take the solution orally twice a day for 1 month. While patients in the placebo group will take Fangji Huangqi pill placebo as the same way as the Fangji Huangqi pill group. Besides that, both groups will administrate Mobic (7.5 mg once a day) in addition.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fangji Huangqi pill or Fangji Huangqi pill placebo
Description: For the treatment group (Fangji Huangqi pill group), patients will administrate Fangji Huangqi pill (4 g) in 200 milliliter hot water as the instruction and take the solution orally twice a day for 1 month. While patients in the placebo group will take Fangji Huangqi pill placebo as the same way as the Fangji Huangqi pill group. Besides that, both groups will administrate Mobic (7.5 mg once a day) in addition.
Study: NCT02929927

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rubber dam isolation
Description: tooth was isolated using a rubber dam in order to avoid the outside microbe

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rubber dam isolation
Description: tooth was isolated using a rubber dam in order to avoid the outside microbe

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aPDT
Description: Inject the photosensitizer (PS)to the parallel orifice of the canal,use the small file to stir the PS for 60 s,then irradiation 120 s.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% iodine tincture
Description: use 1% iodine tincture to disinfect the crown of the teeth.in order to avoid the outside microbe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% iodine tincture
Description: use 1% iodine tincture to disinfect the crown of the teeth.in order to avoid the outside microbe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5%NaClO
Description: use 2.5% NaClO as irrigants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5%NaClO
Description: use 2.5% NaClO as irrigants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root canal preparation
Description: mechanical preparation with NITIMTWO to 25#06, and cleaned with 5 ml of 2.5% NaClO between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2.5% NaClO, 17% EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root canal preparation
Description: mechanical preparation with NITIMTWO to 25#06, and cleaned with 5 ml of 2.5% NaClO between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2.5% NaClO, 17% EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root canal obturation
Description: filled the canals with AH-Plus sealer and Gutta-percha by vertical condensation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root canal obturation
Description: filled the canals with AH-Plus sealer and Gutta-percha by vertical condensation
Study: NCT02043158

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire completion asking questions about quality of life, mood, social support, stress, diet, lifestyle, and demographic information. Questionnaire should take about 60-90 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview asking questions about the amount of stress participant may be having or have had in the past. It should take about 25-30 minutes to complete the interview.
Study: NCT00037752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sibutramine
Description: At the baseline study visit, participants in Group 1 will be given a one month supply of 5 mg/d of sibutramine and a 1-month follow-up visit will be scheduled. After a safety evaluation at the 1-month follow-up visit, participants will have their dose of sibutramine titrated to 10 mg/d, a 1 month supply of the medication will be given to participants, and a 2-month follow-up visit will be scheduled. After a safety evaluation at the 2-month follow-up visit, participants will receive a 1 month supply of sibutramine 10 mg/d and a 3-month follow-up visit will be scheduled. At the 3-month follow-up visit, the sibutramine will be discontinued and participants will be scheduled for 4- and 5-month follow-up visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Smoking Cessation Program
Description: Both groups of participants will take part in a behavioral smoking cessation program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Smoking Cessation Program
Description: Both groups of participants will take part in a behavioral smoking cessation program.
Study: NCT02330016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voluma XC
Description: Voluma XC
Study: NCT04085744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 10% Spray
Description: lidocaine will be apply on the cuff

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone nasal spray
Description: mometasone spray will be applied on the cuff
Study: NCT03282539

Intervention type: DEVICE
Intervention: LAMS
Description: EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents

Intervention type: DEVICE
Intervention: LAMS + pigtail
Description: EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents and a coaxial double pigtail stent
Study: NCT03045133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
Study: NCT00830167

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage: placebo, oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
Study: NCT01462578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacytidine injection: 75 mg/m²/d, subcutaneous; initial minimum 6 cycles; another 6 or 12 cycles according to MRD niveau; maximum 24 cycles
Study: NCT01080586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine Capsules USP (Modified) 100 mg
Description: Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine Capsules USP (Modified) 100 mg
Description: Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
Study: NCT02344472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: endocrine therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: endocrine therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: endocrine therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: endocrine therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK 4/6 inhibitor
Study: NCT02014558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Participants received a single oral dose of 2 mg of midazolam syrup on day -1 and day 15 of cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Participants received a single oral dose of 500 mg cephalexin tablet or capsule on day -1 and day 15 of cycle 1.
Study: NCT03032159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text2Breathe Study Group
Study: NCT04139694

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food plan with cinnamon supplementation
Description: cinnamon twice daily plus follow Cardiometabolic diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food plan without cinnamon supplementation
Description: Cardiometabolic diet only
Study: NCT01365338

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm
Study: NCT02979483

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Integrative supportive care
Description: At the inclusion, the investigator determine a personalized program of supportive care procedures for each patient (for instance : treatment of pain and nutritional support,stenting of bile duct and/or duodenum, tumor biopsy for pathologic diagnosis ,..)~At the end on the integrative supportive care, according to the ECOG-PS of patients , they will be classified into two groups:~* Group 1 :Good prognosis - ECOG-PS 0-1 and eligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel.~Patient will be treated by : FOLFIRINOX or gemcitabine-nab-paclitaxel or clinical trial~- Group 2 : Poor prognosis - ECOG-PS 2-4 and / or ineligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel.~Patients will be treated by: FOLFOX7lightened
Study: NCT02344472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK 4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK 4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK 4/6 inhibitor
Study: NCT03057379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaccine Reminder Recall
Description: The investigators will be sending recall notices via phone call to 11-17 year olds who are eligible but lacking HPV vaccine doses recorded in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaccine Reminder Recall
Description: The investigators will be sending recall notices via phone call to 11-17 year olds who are eligible but lacking HPV vaccine doses recorded in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaccine Reminder Recall
Description: The investigators will be sending recall notices via phone call to 11-17 year olds who are eligible but lacking HPV vaccine doses recorded in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention)
Study: NCT02897765

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEO-PV-01
Description: Personal cancer vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: monoclonal antibody against PD1
Study: NCT02344472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK 4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK 4/6 inhibitor
Study: NCT03981549

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Bone Marrow CD34+ Stem Cells
Description: Single intravitreal injection of autologous bone marrow CD34+ stem cells. The number of cells to be injected per eye will range from 800,000 to 10 million, depending on the yield of the bone marrow aspiration and the isolation procedure.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Autologous Bone Marrow CD34+ Stem Cells
Description: Single intravitreal injection of autologous bone marrow CD34+ stem cells. The number of cells to be injected per eye will range from 800,000 to 10 million, depending on the yield of the bone marrow aspiration and the isolation procedure.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham Therapy
Description: Sham bone marrow aspiration procedure that penetrates the skin, but does not penetrate the bone followed by sham intravitreal injection without penetration of the eye

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Sham Therapy
Description: Sham bone marrow aspiration procedure that penetrates the skin, but does not penetrate the bone followed by sham intravitreal injection without penetration of the eye
Study: NCT03820986

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT02897765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant
Description: immune adjuvant
Study: NCT03075046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue LED 405 nm
Description: It will be applied a 405 nm blue Tonderm LED with a power of 1.66 W / m2, in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session.
Study: NCT03820986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for lenvatinib
Description: Oral capsule
Study: NCT02344472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: chemotherapy
Study: NCT03075046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue LED 405 nm
Description: It will be applied a 405 nm blue Tonderm LED with a power of 1.66 W / m2, in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire of anamnesis
Description: The participants will answer the anamnesis Questionnaire that will be applied by the physiotherapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire of anamnesis
Description: The participants will answer the anamnesis Questionnaire that will be applied by the physiotherapist
Study: NCT04137224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro20
Description: Human normal immunoglobulin for subcutaneous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro20
Description: Human normal immunoglobulin for subcutaneous administration
Study: NCT02344472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin
Description: chemotherapy
Study: NCT04137224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro10
Description: Human normal immunoglobulin for intravenous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro10
Description: Human normal immunoglobulin for intravenous administration
Study: NCT01669928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-hypertensive Medication -
Description: Patients will be taking their routine blood pressure lowering medication prescribed by their GP, different patients will be using different blood pressure lowering medication.~Dosing regimen either in the morning (between 06.00 and 11.00) or in the evening (between 18.00 and 23.00).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-hypertensive Medication -
Description: Patients will be taking their routine blood pressure lowering medication prescribed by their GP, different patients will be using different blood pressure lowering medication.~Dosing regimen either in the morning (between 06.00 and 11.00) or in the evening (between 18.00 and 23.00).
Study: NCT00690222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracameral injection of mydriatic agent
Description: A mixture of 0.2 % tropicamide and 2% phenylephrine will be injected into the anterior chamber at the beginning of surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracameral injection of mydriatic agent
Description: A mixture of 0.2 % tropicamide and 2% phenylephrine will be injected into the anterior chamber at the beginning of surgery